Basiliximab decreases the incidence of acute rejection after intestinal transplantation.
Sudan
D L
DL
University of Nebraska Medical Center, Nebraska Health Systems, Omaha, Nebraska 68198, USA.
Chinnakotla
S
S
Horslen
S
S
Iyer
K
K
Fox
I
I
Shaw
B
B
Langnas
A N
AN
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002675:Child, Preschool; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007223:Infant; D007239:Infections / Q000453:epidemiology; D007422:Intestines / Q000637:transplantation*; D016031:Liver Transplantation / Q000276:immunology; D011183:Postoperative Complications / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab